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The new problem
that is receiving
substantial atten-
tion is in-stent
neoatherosclerosis
and its potential
risk for patients
who largely forgot
about their stents
years ago.
Fooling Mother
Nature remains a
work in progress.Thirty-seven years ago, I stood in front of Andreas Gruentzig’s poster at the American Heart
Association’s Scientiﬁc Session wondering how balloon inﬂation in a coronary artery would lead to
anything good. I told him that it would never work, and I was wrong. However, the coronary artery
did not quietly capitulate to this rude disruption, but fought back with a healing process that kept
undoing the work of the balloon. The evolution of percutaneous coronary intervention has
provided a laboratory for vascular biology research. With every advance in coronary intervention,
we have produced new problems, which require new solutions, which produce new problems. Does
the cycle ever end? Perhaps not, although the struggle has clearly been worth it, as millions of
patients can testify. But, are we ﬁnished?
A balloon opens the obstruction and removes the pressure gradient that was producing
ischemia; however, the elasticity of the artery and the exposure of thrombogenic substrate
frequently lead to acute vessel closure. If not, the cytokines release and the “scar” retraction that
follows leads to restenosis. Stents were the mechanical solution to the mechanical problem, but
Mother Nature did not remain fooled for long; the exuberant healing response, driven in part by
the chronic stretch stimulus, resulted in in-stent restenosis. Brieﬂy, we dreamed that controlling
the components of thrombosis would prove a solution, but it did not. The cell migration and
proliferation seen in restenosis are common mechanisms in cancer and wound healing. So, we
tried radiation, which was shown to have been variously effective in both of those conditions. The
growth of neointima was effectively blocked by radiation brachytherapy, but so was the formation
of well-functioning endothelium. Knowledge of the effectiveness of blocking the cell cycle led to
the inevitable combining of the structural solution of the mechanical problem (stents) with drugs
that suppressed the exuberant healing response (drug-eluting stents). Drug-eluting stents are
where we are now, but has Mother Nature been completely fooled this time? The components
of drug-eluting stents (the scaffold, the polymer, and the drug) have each been implicated in
late stent failure that has not been completely eliminated. New systems are being developed
to change the drug, change or eliminate the polymer, or remove the metal scaffold completely
(bioresorbable stents). Has percutaneous coronary intervention ﬁnally triumphed over Mother
Nature?
After the time for acute closure and restenosis has passed, and the stent is well covered with new
tissue, are we “off the hook?” Perhaps not. The new problem that is receiving substantial attention
is in-stent neoatherosclerosis and its potential risk for patients who largely forgot about their stents
years ago. It is not clear what produces this phenomenon, but histologically, it is made up of lipid-
rich core, macrophage inﬁltration, and sometimes, a thin-cap ﬁbroatheroma. Neovascularity and
intraplaque hemorrhage have been observed. In short, it looks like atherosclerosis of the usual
variety, but perhaps more aggressive. In vivo diagnosis is now also possible, with optical coherence
tomography and near-infrared spectroscopy showing, respectively, the thin-cap ﬁbroatheroma and
the lipid core. Why does this occur in some patients years after apparent healing of the stented
segment and adequate coverage of the stent struts with neointima? The polymer delivery system
has been implicated in producing an inﬂammatory response leading to atheromatous changes. The
drugs used to inhibit cell growth have also been implicated. Scanning electron microscopically-
generated images of the endothelial surface show disordered cells with abnormal gap junctions
instead of the well-ordered cobblestone appearance of normally functioning endothelium. These
changes are reminiscent of those seen after radiation brachytherapy. Could such altered endo-
thelium be more permeable to macrophage inﬁltration and subsequent atherosclerosis?
What is the magnitude of the problem? There are more reports of neoatherosclerotic compli-
cations with ﬁrst-generation stents than with the stents now commonly used. Is this only because
the time passed is greater with ﬁrst-generation stents? Hopefully, improved stents will heal with
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580fewer stimuli for the phenomenon to occur, but there
are millions of ﬁrst-generation stents in our patients’
coronary arteries now. What should the interven-
tional approach be to obstructive in-stent restenotic
lesions that may have neoatherosclerosis? Should
very late restenosis be investigated with optical
coherence tomography? Should interventional
approaches be altered if lipid-rich core and thin-
cap ﬁbroatheroma are observed? Should aggressive
antithrombotic or distal embolic measures be
employed? Will aggressive medical therapy stabilize
or reduce the progression of neoatherosclerosis? Will
the disappearance of the bioresorbable stent
eliminate neoatherosclerosis?Fortunately, most of our patients are doing ﬁne, or if
not, the problem they face most likely arises from parts
of the coronary tree not previously stented rather than
from the stented segment. Nonetheless, the occasional
development of in-stent neoatherosclerosis after we
thought we were out of the woods once again proves
that foolingMother Nature remains a work in progress.Address correspondence to:
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